Effectiveness of implantable cardioverter defibrillator as primary prevention in hypertrophic cardiomyopathy: One year follow-up study

被引:0
|
作者
Fadaam, Hasan Ahmed [1 ]
Al-Musawi, Ali Abdul-Amir [1 ]
Al-Iqabby, Kasim Abbas Ismail [1 ]
机构
[1] Ibn Al Bitar Specialized Ctr Cardiac Surg, Baghdad, Iraq
来源
REVISTA LATINOAMERICANA DE HIPERTENSION | 2023年 / 18卷 / 01期
关键词
Hypertrophic Cardiomyopathy; Implantable cardioverter defibrillator; Sudden cardiac death; SUDDEN CARDIAC DEATH; VENTRICULAR-TACHYCARDIA; EFFICACY; RISK;
D O I
10.5281/zenodo.7778653
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Hereditary hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy and varied clinical manifestations. The worst outcome of this disorder, ventricular fibrillation, is sudden cardiac death (SCD), hence the only effective treatment is an implanted cardioverter-defibrillator (ICD). Objective: ICD as a significant preventative technique for hypertrophic cardiomyopathy to avoid sudden cardiac death, study ICD shock risk factors and predictors, ICD suitable shock and their predictions. Method: In an observational, prospective cohort trial, 33 consecutive men and women got ICD treatment to prevent HCM. Patients aged 35-64 were examined at Ibn Al Bitar Specialist Center for Heart Surgery in 2017 for one-year follow-up. At ICD programming visits, all patients had transthoracic echocardiography and were compared to a previous echo exam. Results: 33 patients completed the investigation, with a mean age of 46.5 +/- 7.1, lowest age 35, highest age 64, and 1.2:1 male-to-female ratio. Non-sustained VT on Holter, family history of sudden cardiac death, repeated syncope episodes, and left ventricular wall thickness <30mm increased ICD implantation. 24.2% had two risks, 12.1% three, and 63.6% one. 36.4% positive ICD treatment, all ATP, and all shocks were tested. 27.3% had excellent ICD shock. Women experienced more ICD shocks than men regardless of age. SCD and syncope in the family elevated ICD shock rates. ICD shock risk was higher in women, repeated syncope, and sudden cardiac death families. ICD treatment helps younger patients, those with a positive family history of sudden cardiac death, non-sustained VT, and larger left ventricular outflow tract diameters. Conclusion: ICD shock is more frequent in women with a family history of SCD, syncope, and numerous risk factors. HCM patients with one risk factor may get an ICD as primary prevention. Several risk factors increase ICD shock risk. Inappropriate shock is linked to advanced age and decreased left ventricular outflow tract.
引用
收藏
页码:20 / 25
页数:6
相关论文
共 50 条
  • [31] Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir, Adaya
    Dorian, Paul
    Rakowski, Harry
    Care, Melanie
    Spears, Danna
    HEART RHYTHM, 2021, 18 (01) : 63 - 70
  • [32] Supraventricular Arrhythmia Induction by an Implantable Cardioverter Defibrillator in a Patient with Hypertrophic Cardiomyopathy
    Akbarzadeh, Fariborz
    Kazemi, Babak
    Pourafkari, Leili
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2010, 33 (03): : 372 - 376
  • [33] Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience
    Weinstock, Jonathan
    Bader, Yousef H.
    Maron, Martin S.
    Rowin, Ethan J.
    Link, Mark S.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (02):
  • [34] Long-term follow-up of arrhythmogenic right ventricular cardiomyopathy patients with an implantable cardioverter-defibrillator for prevention of sudden cardiac death
    Yin, Kang
    Ding, Ligang
    Li, Yuqiu
    Hua, Wei
    CLINICAL CARDIOLOGY, 2017, 40 (04) : 216 - 221
  • [35] Substrate Imaging to Guide Primary Prevention Implantable Cardioverter-Defibrillator in Ischemic Cardiomyopathy Fanciful or Realistic Aim? COMMENT
    Gupta, Ankur
    JACC-CARDIOVASCULAR IMAGING, 2020, 13 (08) : 1767 - 1770
  • [36] Long-term follow-up study of uncertainty and psychosocial adjustment among implantable cardioverter defibrillator recipients
    Mauro, Ann Marie P.
    INTERNATIONAL JOURNAL OF NURSING STUDIES, 2010, 47 (09) : 1080 - 1088
  • [37] Cardiac Sarcoidosis: Electrophysiological Outcomes on Long-Term Follow-Up and the Role of the Implantable Cardioverter-Defibrillator
    Mohsen, Amr
    Jimenez, Alejandro
    Hood, Robert E.
    Dickfeld, Timm
    Saliaris, Anastasios
    Shorofsky, Stephen
    Saba, Magdi M.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2014, 25 (02) : 171 - 176
  • [38] Strength of clinical indication and therapeutic impact of the implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy
    Fumagalli, Carlo
    De Filippo, Valentina
    Zocchi, Chiara
    Tassetti, Luigi
    Marra, Martina Perazzolo
    Brunetti, Giulia
    Baritussio, Anna
    Cipriani, Alberto
    Bauce, Barbara
    Carrassa, Gianmarco
    Maurizi, Niccolo
    Zampieri, Mattia
    Calore, Chiara
    De Lazzari, Manuel
    Berteotti, Martina
    Pieragnoli, Paolo
    Corrado, Domenico
    Olivotto, Iacopo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 353 : 62 - 67
  • [39] The implantable cardioverter defibrillator in primary prevention: a revision of monocentric study group
    Gigli, L.
    Barabino, D.
    Sartori, P.
    Rossi, P.
    Reggiardo, G.
    Chiarella, F.
    Rosa, G. M.
    Bertero, G.
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2014, 15 (08) : 653 - 658
  • [40] Clinical Impact of Nonsustained Ventricular Tachycardia Recorded by the Implantable Cardioverter-Defibrillator in Patients with Hypertrophic Cardiomyopathy
    Francia, Pietro
    Santini, Daria
    Musumeci, Beatrice
    Semprini, Lorenzo
    Adduci, Carmen
    Pagannone, Erika
    Proietti, Giulia
    Volpe, Massimo
    Autore, Camillo
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2014, 25 (11) : 1180 - 1187